Suppr超能文献

集中式混合电子和人工干预提高直接口服抗凝剂依从性的疗效:改善心房颤动患者利伐沙班依从性的智能手机干预(SmartADHERE)随机临床试验。

Efficacy of a centralized, blended electronic, and human intervention to improve direct oral anticoagulant adherence: Smartphones to improve rivaroxaban ADHEREnce in atrial fibrillation (SmartADHERE) a randomized clinical trial.

机构信息

Center for Digital Health, Stanford University School of Medicine, Stanford, CA; VA Palo Alto Health Care System, Palo Alto, CA.

Quantitative Sciences Unit, Stanford University School of Medicine, Stanford, CA.

出版信息

Am Heart J. 2021 Jul;237:68-78. doi: 10.1016/j.ahj.2021.02.023. Epub 2021 Mar 4.

Abstract

BACKGROUND

Improving adherence to direct oral anticoagulants (DOAC) is challenging, and simple text messaging reminders have not been effective.

METHODS

SmartADHERE was a randomized trial that tested a personalized digital and human direct oral anticoagulant adherence intervention compared to usual care. Eligibility required age ≥ 18, newly-prescribed (≤90 days) rivaroxaban for atrial fibrillation (AF), 1 of 4 at-risk criteria for nonadherence, and a smartphone. The intervention consisted of combination of a medication management smartphone app, daily app-based reminders, adaptive text messaging, and phone-based counseling for severe nonadherence. The primary outcome was the proportion of days covered by rivaroxaban (PDC) at 6 months. There were 25 U.S. sites, all cardiology and electrophysiology outpatient practices, activated for a target sample size of 378, but the study was terminated by the sponsor prior to reaching target enrollment.

RESULTS

There were 139 participants (age 65±9.6 years, 30% female, median CHADS-VASc score 3 with IQR 2 to 4, mean total medication burden 7.7±4.4). DOAC adherence was high in both arms with no difference in the primary outcome (PDC 0.86±0.25 intervention vs 0.88±0.25 control, p=0.62) or in secondary outcomes including PDC ≥ 0.80 and medication persistence. Per protocol analyses had similar results. Because of the high overall PDC, the likelihood to answer the primary hypothesis was only 51% even if target enrollment were achieved. There were no study-related adverse events.

CONCLUSIONS

The use of a centralized digital and human adherence intervention was feasible across multiple sites. Overall adherence was much higher than expected despite prescreening for at-risk individuals. SmartADHERE illustrates the challenges of trials of behavioral and technology interventions, where enrollment itself may lead to selection bias or treatment effects. Pragmatic study designs, such as cluster randomization or stepped-wedge implementation, should be considered to improve enrollment and generalizability.

摘要

背景

提高直接口服抗凝剂(DOAC)的依从性具有挑战性,而简单的短信提醒并不有效。

方法

SmartADHERE 是一项随机试验,测试了一种个性化的数字和人工直接口服抗凝剂依从性干预措施与常规护理相比的效果。入选标准为年龄≥18 岁、新处方(≤90 天)利伐沙班用于房颤(AF)、有 4 种非依从性高危标准中的 1 种,以及智能手机。该干预措施包括药物管理智能手机应用程序、基于应用程序的每日提醒、自适应短信提醒和基于电话的严重不依从性咨询。主要结局是 6 个月时利伐沙班的覆盖天数(PDC)。美国共有 25 个地点,全部为心脏病学和电生理学门诊,目标样本量为 378 人,但该研究在达到目标入组人数之前被赞助商终止。

结果

共有 139 名参与者(年龄 65±9.6 岁,30%为女性,中位 CHADS-VASc 评分为 3,四分位距为 2 至 4,平均总药物负担为 7.7±4.4)。在两组中,DOAC 依从性均较高,主要结局(PDC 0.86±0.25 干预组与 0.88±0.25 对照组,p=0.62)或次要结局,包括 PDC≥0.80 和药物持续时间,均无差异。按方案分析结果相似。由于总体 PDC 较高,即使达到目标入组人数,回答主要假设的可能性也只有 51%。无研究相关不良事件。

结论

在多个地点使用集中式数字和人工依从性干预措施是可行的。尽管对高危人群进行了预筛选,但总体依从性远高于预期。SmartADHERE 说明了行为和技术干预试验的挑战,其中入组本身可能导致选择偏差或治疗效果。应考虑使用实用研究设计,如集群随机化或逐步楔形实施,以提高入组率和推广性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验